🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great to be involved with The University of Edinburgh's #industry guest speaker session this week. Thanks to Prof Garry Blakely for the invite and also to the #Biotechnology undergrads for engaging with Fiona Dempsey’s talk on #antibody drug development - and asking some excellent questions!

Here's our new Nature Portfolio #publication in Oncogene Journal showcasing the anti-#cancer effects of our first-in-class #therapeutic agent MDX-124 in multiple tumour types: tinyurl.com/MDXnature Congratulations to our collaborators at ARU and BSMS!

A great night at the BioIndustry Association (BIA) gala dinner yesterday. Thanks to Medicines Discovery Catapult for the invitation and the excellent company - the evening just flew by!

As we strengthen our board ahead of clinical expansion, we welcome Sir Graham Brady MP as a non-executive director. Currently a Member of Parliament at Westminster, Sir Graham brings a wealth of experience to Medannex as we embark on an ambitious programme of #clinicaltrials.

Our recent publication unveils the potential of a ground-breaking therapeutic antibody - Hussein Al Ali Medannex Ltd oncodaily.com/33202.html #Cancer #MedannexLtd #OncoDaily #Oncology #Antibody #CancerCare

@mickcraig101 and I seek applications from motivated students interested in undertaking a 4 year PhD programme in Neuroimmunology, alongside our External Partner Organisation, Medannex. Medical Research Scotland and Medannex Ltd fund this studentship. eur03.safelinks.protection.outlook.com/?url=https%3A%…

Great to discover new developments in the field of #AntibodyDrugConjugates at the 14th World ADC event in London this week. It’s a pleasure to catch up with old colleagues and make new connections in this exciting area of drug development.

On the day of the announcement that #Scotland's thriving #lifesciences sector achieved nearly £10.5 billion turnover in 2021, it was great to celebrate with industry colleagues old and new at LifeScienceAwardScot awards. A big thank you to BioIndustry Association (BIA) for hosting us.

Very pleased to announce the grant of new #patents in the USA, China, Japan and Canada protecting the composition of matter of MDX-124, the first clinic-ready therapy to target #annexin-A1. Read the full story here: lnkd.in/eQu7NMav

Great to make so many new connections at #LSXWorld in London, as we progress through the Phase 1b clinical study of our first-in-class #therapeutic. Thanks to LSX Leaders for inviting our CEO Ian Abercrombie to speak on the #Biotech Leaders stage.

Thanks to Life Science Integrates for a vibrant and thought-provoking #BioIntegrates2024 in #Cambridge. Our Director of Scientific Operations, Dr Fiona Dempsey, thoroughly enjoyed the panel discussions, making valuable new connections and catching up with old friends and collaborators.

Can't wait to unveil details of the first #clinical study (ATTAINMENT) of a therapy targeting #annexin-A1 - a new and unique #cancer target - at the world's largest oncology meeting this weekend. It's always exciting when a new class of medicine enters the clinic! #ASCO24 ASCO

A fabulous weekend at #ASCO24 introducing the first-in-human study of MDX-124 - the first therapy to target #annexin-A1. Great to meet new contacts and long-term collaborators, including Chief Investigator Prof Dan Palmer of Liverpool Clinical Trials Centre (LCTC). More info here: tinyurl.com/MDXASCO

Thrilled to announce an Innovate UK ‘Transforming Cancer Therapeutics’ grant for a £313k project tackling bone cancer in children. We’ll be working with senior scientists at ARU and world-leading paediatric oncologists. Full story: tinyurl.com/MDXgrant

We're grateful for this significant grant from Innovate UK's #CancerTherapeutics programme, to prepare our first-in-class anti-#annexin-A1 therapy (MDX-124) for a clinical study in the rare childhood bone cancer, paediatric #osteosarcoma. #CancerTherapeutics #InnovateUKFunded

Thanks to LSX Leaders for the opportunity to introduce our first-in-class #therapeutic to investors and industry colleagues at #LSXUSA in Boston, MA. We’re excited to share the very encouraging signals emerging from our ongoing Phase 1b #oncology study ('ATTAINMENT').

Just back from a fabulous #ESMO24 discussing the latest exciting updates from our first-in-human study with clinicians and collaborators. We're looking forward to sharing our #Phase1 #oncology data next year.

Excellent article by Innovate UK's Head of Medicines Dr Karen Spink highlighting the importance of putting the #child first when creating future life-changing #cancer therapies. We're proud to be part of this mission. tinyurl.com/IUKpaediatric

Great to catch up with old friends and colleagues in London this week and to make some important new connections as well. Thanks to LSX Leaders for showcasing #Medannex at #Investival.

We enjoyed the vibrant #bioProcessUK conference last week at St Georges Events, Liverpool. Engaging sessions covering policy, trends and #sustainability in #lifesciences as well as many great conversations with industry contacts old and new. BioIndustry Association (BIA)